Similar Posts
Basic Pharmacology: How Methadone Works? Part II The Pharmacology of Opioids by Joycelyn Woods
Education Series Number 5.2 February 2001 (Revised) Joycelyn Woods has a graduate degree in neuroscience and psychopharmacology. She has published in neuroscience journals and is recognized internationally for her methadone advocacy work. She is a recipient of the “Richard Lane Methadone Advocacy Award.” Basic Opioid Pharmacology All natural and synthetic opioids exhibit a three dimensional…
Commentary on the NIH Consensus Development Statement(1) from the Meeting on November 17-19, 1997 Effective Medical Treatment of Heroin Addiction
The National Alliance of Methadone Advocates supports the NIH Consensus Statement on Effective Treatment of Heroin Addiction that was facilitated by the National Institute on Drug Abuse and the National Institute of Health. The imprecate of this special statement should be understood in order to realize the impact that it can have on methadone maintenance…
OPTIMIZING RESPONSE TO METHADONE MAINTENANCE TREATMENT
USE OF HIGHER-DOSE METHADONE By Sarz Maxwell MD & Marc Shinderman MD Center for Addictive Problems 609 N Wells Chicago IL 60610 Abstract Using signs, symptoms and serum methadone levels to guide evaluation, we treated 188 patients in a methadone maintenance program with doses of methadone exceeding 100 mg/d. The mean dose…
American Methadone Treatment Association Opioid Treatment in the 21st Century: Implementing the Vision October 7-10, 2001 St. Louis
American Methadone Treatment Association1 Opioid Treatment in the 21st Century: Implementing the Vision October 7-10, 2001 St. Louis Advocacy Events and Patient Participation NAMA at AMTA Conference 2001 Sunday, October 7th Pre-conference Meeting 9 A.M. to 5 P.M. Unifying the Treatment Community Moderator Todd Rosendale, Center for Substance Abuse Treatment Speakers Fred Christie, AFFIRM (President)…
NAMA Policy Statement: A Commentary on Federal Policy for Patients Receiving Over 100 mgs (Revised)
There are many misperceptions and misunderstanding about the federal regulations and particularly when it comes to issues regarding raising the dose over 100 mgs. Prior to the HIV epidemic in order to raise a patient’s dose it was required for the physician to contact the Food and Drug Administration (FDA) for permission. In the early…
The National Alliance Of Methadone Advocates “Together We Can Make A Difference”
Education Series Number 4 August 1994 Methadone, HIV Infection and Immune Function by Herman Joseph Studies undertaken over the past two decades, primarily by Dr. Mary Jeanne Kreek of The Rockefeller University, and corroborated by other scientists throughout the world have established the long-term medical safety of methadone maintenance treatment (Kreek, 1992; Kreek, 1987; Kreek,…